No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

Maryanne Senna, MD, assistant professor of dermatology at Harvard Medical School, discusses the results of the case and the impact JAK inhibitors have had on the treatment of alopecia areata ...

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

Two JAK inhibitors were recently approved by the United States Food and Drug Administration for severe alopecia areata. Baricitinib, or Olumiant (Eli Lilly/Incyte), was approved for severe ...

for treating individuals with severe-to-very-severe alopecia areata. The trial enrolled subjects who had not previously been ...